Advertisement Ensysce Biosciences receives US notice of allowance for delivery of siRNA - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ensysce Biosciences receives US notice of allowance for delivery of siRNA

Ensysce Biosciences has received a patent from the US Patent Office covering the methods of delivering single walled carbon nanotube (SWCNT) complexes with siRNA for therapeutic applications.

The patent, entitled ‘Single-Walled Carbon Nanotube/Sirna Complexes And Methods Related Thereto’, will extend the intellectual property coverage of Ensysce and add to the extensive package of patents for the use of SWCNT for therapeutic applications licensed to Ensysce worldwide.

According to Ensysce Biosciences, carbon nanotubes provide a means to deliver large biologically active agents through natural barriers within the body and readily into cells in a number of tissues that have previously been difficult to deliver to.

Ensysce Biosciences CEO Dr Lynn Kirkpatrick noted the company’s demonstration of SWCNT delivery of siRNA into tissues and specifically tumors in animal models has allowed us to begin moving this delivery platform into clinical development.

"We have optimized the formulation of our complexes and have begun studies to support our IND that will lead to a clinical trial in the next 12 to 15 months. This Notice of Allowance confirms the novelty of our approach and significantly enhances the scope of our protection," Dr Kirkpatrick added.